Russell Wong, Mariangela G de O Sichmann, James Sun, Alexis R Kim, Robert J Bianchini, Kevin D Hermanson, Louis Chabert
{"title":"In Vitro and In Vivo Assessment of an Innovative Peeling System with Azelaic and Tranexamic Acids for Targeted Hyperpigmentation Reduction.","authors":"Russell Wong, Mariangela G de O Sichmann, James Sun, Alexis R Kim, Robert J Bianchini, Kevin D Hermanson, Louis Chabert","doi":"10.1007/s13555-025-01399-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Melanin, derived from tyrosine, plays a pivotal role in skin pigmentation through melanogenesis. Disruptions in this process lead to hyperpigmentation, a condition affecting skin tone and quality of life. Current treatments, including chemical peels, have limitations, highlighting the need for novel solutions. Here, we present an innovative peeling system, comprising a masque and moisturizer, formulated with a novel blend of acids, including azelaic acid (AZA) and tranexamic acid (TXA), alongside known brightening and penetration-enhancing agents for a comprehensive solution to target hyperpigmentation.</p><p><strong>Methods: </strong>In vitro studies assessed the ability of the novel moisturizer to inhibit ultraviolet-A (UVA)-induced melanin accumulation in human melanocytes. In a single-center, controlled study, we assessed the efficacy of the peeling system in 33 healthy female participants aged 30-55 years with moderate-to-severe hyperpigmentation over a 6-week treatment period. Skin condition was assessed using clinical photography, 3D skin topography, and clinical expert evaluation (CEE) at baseline and 6 weeks post-treatment. Participants completed a self-evaluation questionnaire at 6 weeks post-treatment.</p><p><strong>Results: </strong>In vitro findings demonstrated a concentration-dependent inhibition of melanin accumulation by the novel moisturizer. In vivo, significant reductions in dark spot number, area, and perimeter were observed at week 6, along with improvements in skin homogeneity, contrast, and brightness. Skin tone and roughness parameters also improved significantly from baseline. These findings were supported by self-evaluation findings and improvements in CEE parameters.</p><p><strong>Conclusion: </strong>These data provide evidence for the efficacy of the innovative peeling system in reducing the appearance of hyperpigmentation over a 6-week treatment regimen in females with healthy skin and moderate-to-severe hyperpigmentation. The inclusion of AZA and TXA within the peeling system, along with active brightening and penetration-enhancing ingredients, may have synergistically facilitated the observed improvements. This multifaceted approach may address hyperpigmentation at the source, contributing to overall improvements in the appearance of the skin.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":"15 5","pages":"1209-1225"},"PeriodicalIF":3.5000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12033157/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13555-025-01399-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/20 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Melanin, derived from tyrosine, plays a pivotal role in skin pigmentation through melanogenesis. Disruptions in this process lead to hyperpigmentation, a condition affecting skin tone and quality of life. Current treatments, including chemical peels, have limitations, highlighting the need for novel solutions. Here, we present an innovative peeling system, comprising a masque and moisturizer, formulated with a novel blend of acids, including azelaic acid (AZA) and tranexamic acid (TXA), alongside known brightening and penetration-enhancing agents for a comprehensive solution to target hyperpigmentation.
Methods: In vitro studies assessed the ability of the novel moisturizer to inhibit ultraviolet-A (UVA)-induced melanin accumulation in human melanocytes. In a single-center, controlled study, we assessed the efficacy of the peeling system in 33 healthy female participants aged 30-55 years with moderate-to-severe hyperpigmentation over a 6-week treatment period. Skin condition was assessed using clinical photography, 3D skin topography, and clinical expert evaluation (CEE) at baseline and 6 weeks post-treatment. Participants completed a self-evaluation questionnaire at 6 weeks post-treatment.
Results: In vitro findings demonstrated a concentration-dependent inhibition of melanin accumulation by the novel moisturizer. In vivo, significant reductions in dark spot number, area, and perimeter were observed at week 6, along with improvements in skin homogeneity, contrast, and brightness. Skin tone and roughness parameters also improved significantly from baseline. These findings were supported by self-evaluation findings and improvements in CEE parameters.
Conclusion: These data provide evidence for the efficacy of the innovative peeling system in reducing the appearance of hyperpigmentation over a 6-week treatment regimen in females with healthy skin and moderate-to-severe hyperpigmentation. The inclusion of AZA and TXA within the peeling system, along with active brightening and penetration-enhancing ingredients, may have synergistically facilitated the observed improvements. This multifaceted approach may address hyperpigmentation at the source, contributing to overall improvements in the appearance of the skin.
期刊介绍：
Dermatology and Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of dermatological therapies. Studies relating to diagnosis, pharmacoeconomics, public health and epidemiology, quality of life, and patient care, management, and education are also encouraged.
Areas of focus include, but are not limited to all clinical aspects of dermatology, such as skin pharmacology; skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of aesthetic dermatology, including skin maintenance, dermatological surgery, and lasers.
The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/case series, trial protocols, and short communications. Dermatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an International and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. The journal appeals to a global audience and receives submissions from all over the world.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
